Applications of 1-N-Boc-4-(4-Pyridylmethylamino)Piperidine in Industrial Manufacturing

1-N-Boc-4-(4-Pyridylmethylamino)Piperidine acts as a critical intermediate in multiple high-value synthesis routes within the fine chemical and pharmaceutical manufacturing supply chains. As the producer, we focus on reliable, compliant integration of this intermediate across specialized industrial processes. The following sections outline principal downstream sectors, specific process details, and compliance frameworks observed by commercial users.

1. Oncology Active Pharmaceutical Ingredient (API) Synthesis

In oncology drug production, manufacturers employ this intermediate during advanced API assembly steps. It serves as a protected piperidine moiety contributor in the formation of small-molecule kinase inhibitors, particularly those targeting aberrant cell signaling pathways. Production engineers integrate this raw material in late-stage coupling reactions, ensuring efficient introduction of pyridylmethyl groups with minimized byproduct risk. Batch records require controlled deprotection of the Boc group prior to final purification and crystallization, supporting targeted pharmacological profiles.

Industry compliance standards

• Current Good Manufacturing Practice (cGMP, ICH Q7)
• European Pharmacopoeia (Ph. Eur.) API monograph compliance where applicable
• U.S. FDA 21 CFR Parts 210/211 for finished API
• EMA Guideline on the Chemistry of Active Substances

Typical usage ratio

• 0.15–0.35 molar equivalents per molecule of targeted pharmaceutical intermediate
• Adjustment based on target molecular weight and reaction step specificity

Downstream process integration

• Late-stage synthesis step: Boc removal and coupling to active pharmacophores
• Cleanroom blending with coupling agents and solvents (e.g., DCM, DMF, acetonitrile)
• Sequential chromatographic purification prior to API isolation

Final product types

• Small-molecule oncology APIs (e.g., kinase inhibitors)
• Tablet, capsule, or injectable oncology drug formulations

2. CNS Drug Intermediate Synthesis

Developers of central nervous system medications utilize this intermediate in the construction of piperidine-substituted pyridine backbones. In these routes, chemists depend on its selective N-Boc protection for stepwise coupling to beta-adrenergic and neurotransmitter pathway modulators. Following condensation and Boc deprotection, the resulting advanced intermediates feed into the core structure of anti-depressants or cognition-enhancing molecules. Stringent control over reaction stoichiometry and impurity profiles is demanded by downstream quality review.

Industry compliance standards

• IFPMA and ICH Q11 (Development and Manufacture of Drug Substances)
• GMP requirements for starting materials and intermediates
• Japanese Pharmacopoeia (JP), where applicable in market

Typical usage ratio

• Ranges from 0.20–0.40 molar equivalents per batch, depending on target structure complexity
• Defined by route optimization and upscaling protocols

Downstream process integration

• Introduction as a nucleophilic partner in SN2 alkylation steps
• Controlled Boc removal and purification before integration into CNS-active pharmaceutical precursors
• Final steps managed in closed, automated reactor systems

Final product types

• Anti-depressant and cognitive enhancer API intermediates
• Bulk tablets and finished psychiatric prescription medicines

3. Custom Peptide Conjugate Manufacturing

Specialty peptide manufacturers apply this intermediate during chemical conjugation of piperidine-modified ligands to therapeutic peptides. The protected amine group allows for site-specific addition to lysine side chains or N-terminals, increasing molecular diversity and receptor selectivity. Custom process batches require precision-controlled Boc deprotection steps under anhydrous conditions, prior to further cyclization or labeling. Final purification relies on preparative HPLC for regulatory-grade output.

Industry compliance standards

• ISO 9001/13485 Quality Management Systems
• US FDA QSR for device-linked conjugate substances
• European Pharmacopoeia guidelines for peptide purity

Typical usage ratio

• Typically 0.05–0.10 molar equivalents per peptide or conjugation batch
• Adjusted according to peptide chain length and number of labeling sites

Downstream process integration

• Activation and coupling during final solid-phase peptide synthesis cycles
• Utilized for orthogonal labeling or site-specific tethering prior to cyclization
• Final deprotection and characterization by UPLC-MS

Final product types

• Therapeutic peptides with piperidine-modified side chains
• Imaging or diagnostic peptide conjugates

4. High-Purity Research Chemical Production

Laboratory chemical suppliers require this intermediate to produce high-purity, piperidine-bearing research standards and molecular probes. Synthesis routes exploit the N-Boc protection for stepwise assembly of combinatorial small molecule libraries. Technicians perform Boc deprotection under monitored, batch-specific conditions to avoid contamination, followed by solvent exchange and high-vacuum drying. Final QC involves both NMR and HPLC area percentage analysis before release.

Industry compliance standards

• ISO 17034 for reference material producers
• REACH Pre-registration and downstream user obligations (EU markets)
• GLP (Good Laboratory Practice) for analytical chemical suppliers

Typical usage ratio

• Varies between 0.05–0.25 molar equivalents for each target reference material
• Defined based on target molecular framework and intended research application

Downstream process integration

• Introduction in multi-step library or probe synthesis as a protected amine precursor
• Employed in parallel batch assembly under inert conditions
• Final crude subjected to high-purity chromatographic refining before packaging

Final product types

• Analytical chemical standards with defined piperidine substituents
• Precursor molecules for high-throughput screening in drug discovery